linjc16/ctgov huggingface dataset:
Why Join a Walking Program?

Study Overview
=================
Brief Summary
-----------------
The purpose of this interview study is to learn why adults would join a walking program. This study involves interviews with persons who are 65 years of age or older. The interview takes approximately 25 minutes. A total of 132 people will be enrolled. This study will examine the utility or value of various potential features of an incentive-based walking program. These data will enable us to monitor and improve upon enrollment of incentive-based walking programs.

Official Title
-----------------
Why Join a Walking Program?

Conditions
-----------------
Older Adults

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: age 65 or older self rated health at least good on a scale of poor, fair, good, very good, excellent self reports no physical reason not to exercise or health condition that would interfere with being active self reports able to walk at least 2 blocks without assistance or stopping not participating in a daily walking exercise program

Ages Eligible for Study
-----------------
Minimum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Adults ages 65 and older<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Willingness to Participate | The goal of this pilot project is to examine why adults would join an incentive-based walking program. Our focus is willingness to participate. Willingness to participate is measured on a 7 point ordinal scale. | Participation in the study will include only one interview, lasting approximately 25 minutes. Willingness to participate will be assessed during this first and only interview with the participant. | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Self explicated conjoint task | This study will examine the utility or value of various potential features of an incentive-based walking program. These data will enable us to monitor and improve upon enrollment of incentive-based walking programs. How important is this feature? How desirable is this feature? Importance: 7 point ordered scale from extremely to not at all Desirability: 7 point from very desirable to very undesirable | Participation in the study will include only one interview, lasting approximately 25 minutes. The self explicated conjoint task will be assessed during this first and only interview with the participant. | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
elderly, walking, incentives
Safety, Efficacy, and Pharmacokinetics Study of Tarceva to Treat Advanced Colorectal Cancer

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is test the safety of Tarceva, find the best dose, and see what effects (good and bad) it has on you and your colorectal cancer. The effects of Tarceva will be evaluated in combination with 5-fluorouracil, leucovorin, and irinotecan, with or without Bevacizumab.

Official Title
-----------------
Open-Label, Multicenter, Dose-Escalation Study in Subjects w/Advanced Colorectal Cancer to Evaluate the Safety, Efficacy, and Pharmacokinetics of Tarceva in Combination w/5-Fluorouracil, Leucovorin, and Irinotecan and of Bevacizumab in Combination w/Tarceva, 5-Fluorouracil, Leucovorin, and Irinotecan

Conditions
-----------------
Colorectal Cancer

Intervention / Treatment
-----------------
* Drug: Erlotinib (aka Tarceva or OSI-774)
* Drug: Bevacizumab (aka Avastin or Rhu MAb VEGF)


Participation Criteria
=================
Eligibility Criteria
-----------------
Subjects must fulfill all of the following criteria to be eligible for study entry: Signed informed consent At least 18 years of age Histologically confirmed metastatic colorectal adenocarcinoma of the colon or rectum Resected or biopsied primary tumors or metastatic site will serve as the basis for histologic confirmation. Measurable disease (defined as at least one dimension >2 cm [>1 cm on spiral CT scans]) ECOG performance status of 0 or 1 Life expectancy >3 months Use of an effective means of contraception in men and in women of childbearing potential Ability to comply with study and follow-up procedures

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Erlotinib (aka Tarceva or OSI-774)|nan|
|Drug: Bevacizumab (aka Avastin or Rhu MAb VEGF)|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
A Single-center Retrospective Study to Find Prediction Factors Related to Mortality of COVID-19 Patients.

Study Overview
=================
Brief Summary
-----------------
In the single-centered, retrospective study, 306 hospital patients (including 129 diabetes and 177 non-diabetes patients) confirmed with SARS-CoV-2 infection were enrolled in Tongji Hospital, Wuhan, China. Clinical characteristics including clinical manifestation, laboratory parameters, lung CT features and clinical outcomes were compared between diabetes and non-diabetes patients. The prediction factors were analyzed for mortality of COVID-19 by univariate and multivariate analysis.

Official Title
-----------------
A Single-center Retrospective Study to Find Prediction Factors Related to Mortality of COVID-19 Patients by Univariate and Multivariate Analysis.

Conditions
-----------------
COVID-19

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients admitted from Feb 2, 2020 to Feb 15, 2020, diagnosed with SARS-CoV-2 pneumonia according to interim guidance of National health commission of the people's republic of China. Exclusion Criteria: With SARS-CoV-2 RNA detection negative results.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Diabetes<br>Diabetes mellitus was diagnosed according to the standards of American Diabetes Association which were briefly described as FPG ≥ 7.0 mmol/L (Fasting is defined as no caloric intake for at least 8 h) or 2-h plasma glucose ≥ 11.1 mmol/L during Oral glucose tolerance test (OGTT), or with classic symptoms of hyperglycemia or hyperglycemic crisis, a random plasma glucose (RPG) ≥ 11.1 mmol/L. And in this group, we have 129 COVID-19 patients with diabetes. | |
| Non-diabetes<br>Patients who do not meet the American Diabetes Association's standard diagnosis of diabetes are defined as non-diabetes. And in this group, we have 177 COVID-19 patients without diabetes. | |
| Survivors<br>COVID-19 patients who survived on the 28th day in hospital belong to survivors group. In the survivors group, we included 201 patients with complete data. | |
| Non-survivors<br>COVID-19 patients who did not survive on the 28th day in hospital belong to non-survivors group. In the non-survivors group, we included 54 patients with complete data. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Find the prediction factors associated with hospitalized death of patients with COVID-19 by univariate and multivariate analysis |  | 28 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Demographics and clinical characteristics |  | 28 days | 
| Laboratory parameters and radiography image features |  | 28 days | 
| Treatment, complications and clinical outcomes |  | 28 days |
The Role of Genetic Factors in the Development of Bronchial Asthma in the Kazakh Population

Study Overview
=================
Brief Summary
-----------------
To research for a genetic marker of bronchial asthma, a single nucleotide polymorphism (SNP) analysis of DNA obtained from the peripheral blood of patients with bronchial asthma and normal control will be performed.

Detailed Description
-----------------
Unrelated Kazaks subjects who have bronchial asthma were recruited in the current study. Genotyping for various SNP associated due to the linkage disequilibrium patterns is to be performed. Genotypes would be statistically compared between patients with bronchial asthma and normal control subjects free of bronchial asthma

Official Title
-----------------
Preventive and Personalized Medicine (2021-2023)

Conditions
-----------------
Bronchial Asthma, Genome Wide Association Studies

Intervention / Treatment
-----------------
* Genetic: SNP analysis of the DNA


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Persons with bronchial asthma confirmed by a doctor; The age of the patients is from 5 to 60 years; Persons of Kazakh nationality, whose paternal and maternal grandparents are Kazakhs. Persons who are able and willing to provide written informed consent; Persons capable and willing to comply with the research protocol; Exclusion Criteria: Persons who, in the opinion of the researcher, are mentally or legally incapacitated, which prevents obtaining informed consent; Pregnant or lactating women; Tuberculosis of any localization in the active phase and in history; Severe and decompensated diseases of the liver and kidneys, cardiovascular system; Severe and decompensated course of endocrine diseases; Autoimmune diseases; Systemic diseases; Oncological diseases;

Ages Eligible for Study
-----------------
Minimum Age: 5 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental group:<br>Patients with bronchial asthma | Genetic: SNP analysis of the DNA<br>* SNP analysis of the DNA obtained from peripheral blood sample<br>|
| Control group<br>Patients without bronchial asthma | Genetic: SNP analysis of the DNA<br>* SNP analysis of the DNA obtained from peripheral blood sample<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| number of SNPs associated with bronchial asthma | Using SNPsto identify candidate genes associate with bronchial asthma | 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Bronchial Asthma, Genome Wide Association Studies
The Study of Clinical Value of Acute Physiologic and Chronic Health Evaluation (APACHE) Scoring System in Medical Intensive Care Unit

Study Overview
=================
Brief Summary
-----------------
Objective: To evaluate and compare the outcome predictive power of Acute Physiologic and Chronic Health Evaluation (APACHE) Ⅳ、Ⅲ、Ⅱ scoring systems for intensive ill patients in an independent medical intensive care unit (MICU), and explore the best time point when they can most accurately predict outcome. Design: Retrospective analysis of medical records. Methods and Materials: Collect data of patients admitted between July 2010 and July 2013 to the medical intensive care unit of the First Affiliated Hospital of Sun Yat-sen University in Guangzhou, China. Patients with an ICU stay less than 4 hours and age less than 16 years were excluded. Calculate the APACHE Ⅳ、Ⅲ、Ⅱ scores and corresponding predictive mortality risks in the first 24 hours of ICU admission and the 3th, 5th, 7th, 14th, 21 th, 28th day or the day of transferred out of ICU or death. The predictive power of each model was assessed through the ratio of observed death rates and predictive death rates (Standardized mortality ratios, SMR), the calibration of observed and predictive death rates and the discriminative ability between survivors and non-survivors. Hosmer-Lemeshow test was employed for assessing the calibration and the discriminative ability was assessed by the area under the receiver operating curve. Compare the predictive power of the three models at different time points and explore the the best time point when they can most accurately predict outcome.

Conditions
-----------------
APACHE Scoring Systems, Intensive Care Units, Outcome Prediction, Mortality

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with an ICU stay more than 4 hours and age older than 16 years. Exclusion Criteria: Patients with an ICU stay less than 4 hours and age less than 16 years.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
ICU
Surveillance Study of Bacterial Contamination of the Parent's Cell Phone in the NICU

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine the contamination rate of the parents cell phone in a newborn intensive care setting and identify the types of bacteria contaminating the cell phone as well as evaluating the effectiveness of an antimicrobial gel in reducing the transmission of bacteria from the cell phone to the parents hands.

Detailed Description
-----------------
J Perinatol. 2013 Dec;33(12):960-3. doi: 10.1038/jp.2013.108. Epub 2013 Sep 5.

Official Title
-----------------
Surveillance Study of Bacterial Contamination of the Parent's Cell Phone in the NICU and the Effectiveness of an Antimicrobial Gel in Reducing Transmission to the Hands

Conditions
-----------------
Bacterial Contamination Rate of the Cell Phones

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Parents with a cell phone Exclusion Criteria: Parents that do not have a cell phone

Ages Eligible for Study
-----------------
Minimum Age: 13 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Determine contamination rate of parents cellphone in the NICU and identify types of bacteria on cell phones while evaluating the effectiveness of antimicrobial gel in reducing the transmission of bacteria from cellphone to parents hands. |  | contamination rate through bacterial swabs | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
bacterial contamination
Clinical Trial to Compare the Pharmacokinetics and Safety of Eperisone HCl SR Tablet 75mg and Myonal Tablet 50mg

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to Evaluate and Compare Safety and Pharmacokinetic of the Eperisone HCl SR and Myonal in healthy Korean male adults.

Detailed Description
-----------------
Myonal: Eperisone Hydrochloride (muscle relaxant)

Official Title
-----------------
A Phase I Clinical Trial to Compare the Pharmacokinetics and Safety of Eperisone HCl SR Tablet 75mg and Myonal Tablet 50mgafter Oral Administration in Healthy Male Subjects.

Conditions
-----------------
Low Back Pain

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Healthy male subjects age between 20 and 55 singed informed consent Exclusion Criteria: Hypotension or hypertension has a history of allergy reaction of this drug or other drugs

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 55 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Eperisone SR tablet 75mg, Myonal 50mg<br>Eperisone SR tablet 75mg Myonal 50mg | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Auclast, Cmax |  | Eperisone SR 0-24h, Myonal 0-24hr | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| AUCinf, Tmax, t1/2, Css,min, Tss,max |  | Eperisone SR 0-24hr, Myonal 0-24hr |
Breath Gas Analysis for the Diagnosis of Breast Cancer

Study Overview
=================
Brief Summary
-----------------
The volatile content of the exhaled breath gas of mamma carcinoma patients will be chemically analyzed by proton-transfer-reaction time of flight mass spectrometry. The goal of the study is to determine typical breath gas components that allow to distinguish patients with mamma carcinoma from women without carcinoma. Further, the investigators will test whether these breath gas markers can be used as tumor markers, which change in a typical manner during the progress of the disease. Finally the data will be investigated for the presence of marker components, that identify patients who will develop metastasis.

Official Title
-----------------
Leistungsbewertungsprüfung: Atemluftanalyse für Die Diagnose Von Brustkrebs, für Die Überwachung Der Therapie Und für Die Voraussage Des Metastasenrisikos

Conditions
-----------------
Mamma Carcinoma

Intervention / Treatment
-----------------
* Device: Breath Collecting Unit
* Device: Breath Collecting Unit


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Mamma carcinoma diagnosed by histology (cases) Mamma carcinoma excluded by radiology (controls) At the time of diagnosis before surgery At the beginning and during chemotherapy; Exclusion Criteria: No informed consent form singed

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Mamma Carcinoma, no treatment<br> | Device: Breath Collecting Unit<br>* Collect two breath gas samples per patient on one day before surgery<br>* Other names: BCU;|
| Mamma Carcinoma, treatment<br> | Device: Breath Collecting Unit<br>* Collect two or more breath gas samples on different days during adjuvant or neo-adjuvant therapy.<br>* Other names: BCU;|
| No Mamma Carcinoma diagnosed by X-ray<br> | Device: Breath Collecting Unit<br>* Collect two breath gas samples per patient on one day before surgery<br>* Other names: BCU;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Breath gas markers | Breath gas markers that allow to distinguish patients with mamma carcinoma from women without carcinoma; | 3 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Breath gas analysis, Volatile components in exhaled breath
Neuroanatomy of Reading in Congenital Deafness.

Study Overview
=================
Brief Summary
-----------------
The aim of the research is to investigate phonological processing in deafness and to examine its influence on the neuroanatomy of reading.The basic hypothesis is that insofar as the ability to read is closely related to the ability to segment and represent speech units, the neuroanatomy of reading in deaf would be different from the one of hearing readers.

Official Title
-----------------
Phonological Perception and Learning to Read : the Neuroanatomy of Reading in Congenitally Deaf Persons

Conditions
-----------------
Congenital Deafness

Intervention / Treatment
-----------------
* Procedure: fMRI


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria: adult full education Exclusion criteria: reading impairment fMRI

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: fMRI|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Neuropsychology, fMRI, Reading, Phonology, Deafness
Lifestyle Interventions to Reduce Diabetes Risk

Study Overview
=================
Brief Summary
-----------------
Type 2 diabetes is more frequent in Japanese Americans than in Japan or the U.S. non-Hispanic white population. This appears to be due to the effects of ''westernization'' to bring out metabolic changes that lead to diabetes. This study will look at whether increased physical activity and dietary changes will reduce or prevent the metabolic changes that lead to type 2 diabetes in Japanese Americans who have impaired glucose tolerance, a condition intermediate between normal glucose tolerance and diabetes.

Official Title
-----------------
Interventions to Reduce Diabetic Risk in Japanese Americans

Conditions
-----------------
Glucose Intolerance, Diabetes Mellitus, Type 2

Intervention / Treatment
-----------------
* Behavioral: exercise and diet


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Japanese American Confirmed impaired glucose tolerance Able to fill out questionnaires Exclusion Criteria: Significant exercise-restricting disease Poorly controlled hypertension Psychiatric disease or dementia Already on unusually restrictive diet Use of hypolipidemic drugs Use of tobacco Abnormal blood screening tests ECG evidence of ischemic heart disease at rest Abnormal maximal Bruce treadmill test

Ages Eligible for Study
-----------------
Minimum Age: 40 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized


Arms and Interventions

| Intervention/Treatment |
| --- |
|Behavioral: exercise and diet|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
low fat diet, aerobic exercise, impaired glucose tolerance, Japanese Americans, metabolic risk factors